Kornimate/medical-research-clean huggingface dataset:
clinical efficacy of disulfiram in laam-maintained cocaine abusers

Conditions: Cocaine-Related Disorder; Opiate Dependence

Summary: this 18-week, randomized, double blind clinical trial provided treatment for 160 cocaine-dependent opioid addicts, aged 18-65 years. participants were stabilized on laam maintenance during the first 4 weeks and cocaine use was assessed; participants were then stratified by level of cocaine use and randomly assigned to receive one of the following: placebo disulfiram (0 mg/day), disulfiram at 62.5 mg/day, disulfiram at 125 mg/day, or disulfiram at 250 mg/day. during induction onto laam, participants were administered increasing doses of laam plus placebo disulfiram on a thrice-weekly basis until maintenance doses of laam are attained. at the beginning of week 5, participants received laam plus disulfiram or placebo disulfiram according to their randomized assignments, and were maintained on these agents through week 16. at the end of the study, participants underwent detoxification from laam and active/placebo medication over a 4- to 6-week period. all participants received weekly 1-hour psychotherapy (cognitive behavioral treatment) with experienced clinicians specifically trained to deliver the therapy and who received ongoing supervision. the primary outcomes were retention and reduction in opioid and cocaine use, as assessed by self-report and confirmed by thrice-weekly urinalyses. secondary outcomes included reductions in other illicit drug and alcohol use, as well as improvements in psychosocial functioning.


Eligibility criteria:
inclusion criteria: * between the ages of 18-65 years. * are not currently enrolled in treatment. * participants must demonstrate opioid dependence, as evidenced by documentation of prior opioid agonist maintenance and/or have signs of withdrawal upon administration of naloxone (\<0.8 mg, i.m.), and an opioid-positive urine screen. * participants also must be current users of cocaine with self-reported use of \> 7 gm during the preceding 12 months, self-reported use of \> 1 time/week in at least one month preceding study entry, and cocaine-positive urine screen. * participants must fulfill dsm-iv criteria for opioid and cocaine dependence. exclusion criteria: * current diagnosis of other drug or alcohol physical dependence (other than opiates, cocaine or tobacco) * significant medical conditions such as abnormal liver function (with laboratory findings greater than three times normal). * active hepatitis; hypertension; a current cardiac condition or high risk of cardiovascular disease; seizure disorders; or another significant underlying medical condition which would contraindicate disulfiram or laam treatment. * meets dsm-iv psychiatric classifications for schizophrenia, bipolar disorder, or other psychotic disorders; exhibiting current suicidality or homicidality; current use of a prescribed psychotropic medication that cannot be discontinued. * pregnancy.
telehealth system to improve quality of life in breast cancer survivors

Conditions: Breast Cancer

Summary: background: cancer is increasingly viewed as a chronic disease and therefore there is a growing need for long-term treatments. breast cancer survivors suffer physical impairment after oncology treatment. this impairment reduces quality of life (qol) and increases the prevalence of conditions associated to unhealthy life-style. objective: the overall objective of e-cuidate telerehabilitation will be to evaluate short and long-term effects telehealth program. methods: seventy-two breast cancer survivors (age range: 18-65 years) will be recruited through oncology and breast units at the virgen de las nieves hospital and san cecilio hospital and associations of breast cancer patients in granada. patients will be randomized to receive the online rehabilitation group (n=36) or usual care (control) group (n=36). telerehabilitation group will receive an eight-week online intervention and control group receive recommendations about usual care. discussion: the investigators study attempts to increase the level of fitness and reduce musculoskeletal disorders in breast cancer patients through a strategy for care based on telerehabilitation to promote therapeutic exercise.


Eligibility criteria:
inclusion criteria: * diagnosis of stage i, ii, or iiia breast cancer * medical clearance of participation * without chronic disease or orthopaedic that would interfere with ability to participate in a physical activity program * access to internet * basic ability to use the computer or living with a relative who has this ability * completion of adjuvant therapy except for hormone therapy * no history of cancer recurrence * have interest in improving lifestyle: fitness/stress level * have signed informed consent

Keywords: telehealth fatigue breast cancer exercise quality of life telerehabilitation
the pediatric eating assessment tool

Conditions: Cerebral Palsy

Summary: there is no dysphagia spesific and patient/parent centered outcome instrument in the pediatric population. the purpose of this investigation is to develop the pediatric version of the eating assessment tool (pedi-eat-10) and investigate its validity and reliability.

the evaluation of pediatric swallowing disorders includes clinical and instrumental techniques. the clinical evaluation is important for clinical decision-making and to assess the need for an instrumental evaluation of swallowing. a recent systematic review suggested that the currently available non-instrumental assessments for clinicians to evaluate swallowing and feeding function in the pediatric population have wide variations in design, assessment domains, and target groups. it was concluded that there is a significant need for standardized assessment tools with good psychometric properties in the pediatric population. the existing instruments measure the presence or absence and frequency of challenges related to eating/feeding problems in pediatrics, they do not comprehensively measure oropharyngeal phase swallowing problems or do not reflect the severity of oropharyngeal dysphagia symptoms. the 10-item eating assessment tool (eat-10), which was designed for adult patients, is a good model for this current research. it has proven highly successful in quantifying initial dysphagia symptom severity and in monitoring treatment efficacy in a vast array of dysphagia etiologies. although the eat-10 is a symptom survey, it has been able to predict objective evidence of swallowing dysfunction. there is no dysphagia spesific and patient/parent centered outcome instrument in the pediatric population such as the eat-10. the purpose of this investigation is to develop the pediatric version of the eating assessment tool (pedi-eat-10) and investigate its validity and reliability.

Eligibility criteria:
the inclusion criteria are: * age above 18 months, * fed orally, * referred due to parent complaints about their child's swallowing function, * not admitted a swallowing center before. the exclusion criteria are: * age below 18 months, * fed nonorally, * no parent complaints about their child's swallowing function, * admitted a swallowing center before.

Keywords: deglutition deglutition disorders pediatric dysphagia swallowing
safety and preliminary efficacy study of gx-i7 in patients with covid-19

Conditions: Covid19

Summary: this study is a phase 1b clinical trial to investigate the safety and preliminary effects of a single dose of a test drug or placebo to the subjects who has diagnosed as covid-19 infection.

this study is a phase 1b clinical trial to investigate the safety and preliminary effects of a single dose of a test drug or placebo to the subjects who has diagnosed as covid-19 infection. study design: prospective, randomized, placebo-controlled, single-blind, single-center

Eligibility criteria:
key inclusion criteria: 1. subjects who have been confirmed to be covid-19 corresponding to mild cases of severity categorization classified by fda through polymerase chain reaction (pcr) test or virus gene test (sequencing) and who can be available to be administered within seven days from the date of manifestation. 2. subjects who are or will be inpatient. key exclusion criteria: 1. patients with symptoms of moderate or higher in the severity classification presented by fda have evidence of lower respiratory tract infection in their imaging findings or need supplemental oxygen therapy or mechanical respiration (ie, non-invasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, etc) 2. subjects with infectious diseases such as bacteremia or severe pneumonia requiring active treatment within four weeks prior to the ip administration
study of talnetant versus placebo and risperidone in schizophrenia

Conditions: Schizophrenia

Summary: this study will evaluate whether talnetant (200mg, 400mg, 600mg) twice a day is effective compared to placebo and risperidone 1-3mg twice a day in treating the positive and negative symptoms of schizophrenia. study subjects will be treated with study drug for up to 6 weeks and will then return for a follow-up visit 2 weeks later. about 275 patients with schizophrenia will be enrolled in this study.


Eligibility criteria:
inclusion criteria: * subjects must have schizophrenia which is not secondary to another medical condition or substance abuse. * require inpatient hospitalization. * woman may enroll only if they are not of child-bearing potential or are on a protocol-approved birth control method. exclusion criteria: * subject is in their first episode of schizophrenia. * subject has other psychotic disorders or bipolar disorder. * subject has schizophrenia symptoms from taking another medicine or drug of abuse, or due to a general medical condition. * subject has a recent history of substance dependence/dependence, or tests positive for illicit drug. * subject has an unstable medical disorder, or any significant medical disorder including autistic disorder, organic brain disease, liver dysfunction, epilepsy or seizures, or is at increased risk of developing cerebrovascular problems like stroke. * subject has any significant abnormalities in any of the screening tests (ecgs, labs, physical examinations, etc.). * subject poses a current serious suicidal or homicidal risk. * subject has a positive pregnancy test, or is lactating or planning to become pregnant within one month of the study. * subject has recently or is currently participating in another clinical study. * subject is stabilized on their current schizophrenia treatment. * subject needs to take any of the medicines not permitted in the study, or has recently had ect (electroconvulsive therapy) or tms (transcranial magnetic stimulation). * subject was non-responsive to two or more adequate trials of antipsychotic treatments over the past 2 years. * subject has had an allergic or significant reaction to any of the study drugs, or can't take risperidone.

Keywords: paranoid catatonic undifferentiated types disorganized
a study of tqb3455 tablets in subjects with advanced malignancies

Conditions: Advanced Malignancies

Summary: this is a open-label, multicenter, phase i study to evaluate tolerance and pharmacokinetics of tqb3455 tablets in subjects with advanced malignancies.


Eligibility criteria:
inclusion criteria: * 1. ≥ 18 years old； eastern cooperative oncology group (ecog) performance status score of 0 to 2; life expectancy ≥12 weeks. 2. has idh2 gene mutation will be selected preferentially. 3. the toxicity of radiotherapy or other antitumor therapy should return to grade 1. 4. no pregnant or lactating women, all the participants should use contraceptives. 5. understood and signed an informed consent form. 6. advanced/metastatic solid tumors or refractory/recurrent acute myeloid leukemia. 7. at least one measurable lesion for solid tumors. 8. adequate organ system function. exclusion criteria: * 1.relapsed after bone marrow transplantation. 2.has received systemic antitumor therapy or radiation therapy within 3 weeks before the first dose. 3.has participated in other clinical trial within four weeks before the first dose. 4.has multiple factors affecting oral medication. 5.has uncontrolled, active systemic fungal, bacterial, or viral infections. 6.poorly controlled hypertension. 7.has serious cardiovascular disease. 8.has drug abuse history that unable to abstain from or mental disorders. 9.has active hepatitis b or c. 10.have a history of immunodeficiency. 11.according to the judgement of the researchers, there are other factors that subjects are not suitable for the study. 12.has central nervous system metastasis with the exception of glioma subjects. 13.has severe life-threatening complication of leukemia, such as uncontrolled bleeding, hypoxia or shock pneumonia, and disseminated intravascular coagulation. 14.has central nervous system leukemia.
gut organoid study

Conditions: Gut Inflammation

Summary: the study will compare basic properties of gut epithelia of hypertensive and normotensive reference subjects. the study will determine if there are fundamental differences in the gut epithelium in hypertension compared to normotension.


Eligibility criteria:
inclusion criteria: * inclusion/exclusion criteria for hypertension participants * ages: 18-80 years old with a weight greater than or equal to 110 lbs * diagnosis of hypertension or without hypertension for the reference cohort. 2017 acc/aha (american college of cardiology/american heart association) definition for hypertension (systolic blood pressure ≥130 mmhg and/or diastolic bp ≥80 mmhg) will be used. * scheduled elective colonoscopy exclusion criteria: * hypertensive or reference individuals with history of autoimmune disease or other chronic inflammatory conditions. * pregnant or have been pregnant in the last six months. * antibiotic treatment within two months of study enrollment * currently taking a medication (e.g. antibiotic, anti-inflammatory agents, glucocorticoids, other immune modulating medications, antacids or proton pump inhibitor drugs like prilosec) known to modify gut microbiota. * unwilling to discontinue using probiotics for at least two weeks before scheduled biopsy. * history of intestinal surgery, inflammatory bowel disease, celiac disease, lactose intolerance, chronic pancreatitis or other malabsorption disorder. * history of blood transfusion within 4 weeks. * subjects who, in the opinion of the investigator, will be uncooperative or unable to comply with study procedures
neoadjuvant chemotherapy versus standard treatment in patients with locally advanced colon cancer

Conditions: Colon Cancer

Summary: the purpose of this study is to compare 3 cycles of neoadjuvant (preoperative) chemotherapy + operation with the standard treatment of locally advanced colon cancer, which is operation + 8 cycles of (adjuvant) chemotherapy. patients receiving neoadjuvant chemotherapy may not need adjuvant chemotherapy after the operation and, if this is the case, they will be spared of 5 cycles of chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically verified locally advanced t3 (eti \> 5 mm) or t4 colon cancer assessed by ct scan. * age ≥ 18 years * ps 0-2. * hematology anc ≥1.5x10\^9/l. thrombocytes ≥ 100x10\^9/l. * biochemistry bilirubinemia ≤ 3 x upper normal level. alat ≤ 5 x upper normal value * consent to translational research * fertile women must present a negative pregnancy test and use secure contraceptives during and 3 months after treatment. * written and orally informed consent. exclusion criteria: * patients with distant metastases. * acute operation * clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before inclusion. * active, serious infection or other serious disease. * peripheral neuropathy nci grade \> 1 * other malignant disease within 5 years prior to study enrollment, except basocellular or squamous skin cancer and carcinoma in situ cervicis uteri. * other investigational treatment within 30 days prior to treatment start. * hypersensitivity to one or more of the active or auxiliary substances.

Keywords: locally advanced colon cancer neoadjuvant chemotherapy
evolving methods to combine cognitive and physical training for individuals with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: this study aims to investigate and compare the intervention effects of combining exercise and cognitive training (either sequentially or simultaneously in a dual-task paradigm) in elderly with mild cognitive impairment. the investigators hypothesize that (1) both sequential and dual-task training can induce greater improvements in the outcome measures than single mode of training; (2) the improvement in cognitive functions and other outcomes may differ between the groups.

background and study aims: mild cognitive impairment (mci) or minor neurocognitive disorder is a syndrome defined as an intermediate stage between cognitively intact and clinically diagnosed dementia. the age-adjusted prevalence of mci in taiwan is approximately 18%, while women have higher prevalence for mci than men. the progression rate from mci to dementia ranges from 10 to 15% each year, and over 50% of the mci population will develop into severe cognitive impairment or dementia in 5 years. therefore, early detection of the individuals who manifest mci and provide appropriate interventions may help reduce the burden of their caregivers and the medical expenses of the health-care system. previous studies found that cognitive training or exercise has emerged as an important therapeutic approach for individuals with mci. however, the intervention effects of combining exercise and cognitive training remain to be determined. furthermore, whether exercise and cognitive training should be administered in sequential order or simultaneously is an important question to pursue. the overall goal of this study is to determine and compare the intervention effects cognitive training, exercise, and combining cognitive and exercise training in individuals with mci. who can participate? individuals with mci. what does the study involve? the participants will receive a total of 36 training sessions, and each session will contain 90 minutes of training. training frequency will be 2-3 times per week for 12-18 weeks. all participants will received pretreatment test, post treatment test, and a 6-month follow-up test. what are the possible benefits and risks of participating? the possible benefits include improvement in cognitive, physical, and daily functions. there are no risks for participating. where to conduct the study? the investigators anticipate recruiting a total of 80 participants from geriatric day care centers and nursing homes from multiple cities in taiwan.

Eligibility criteria:
inclusion criteria: 1. able to follow instruction, 2. clinical dementia rating (cdr) = 0.5 or 1, 3. self- or informant-reported memory or cognitive complaint, and 4. able to perform activities of daily living (barthel index ≥ 70). exclusion criteria: 1. recent myocardial infarction, 2. heart failure, 3. recent heart surgery, 4. severe asthma, 5. concomitant with other neurological disorders, or 6. joint deformity that might prevents them performing exercise or cognitive training.

Keywords: mild cognitive impairment exercise cognitive training
prospective study of diagnostic accuracy of spectral ct for the detection of bone marrow edema

Conditions: Fractures, Bone; Bone Marrow Edema

Summary: dual-energy/multi-energy/spectral-ct can visualize bone marrow edema associated with fractures, however, current scientific evidence is mostly derived from to retrospective analyses. our prospective study systematically analyzes the diagnostic accuracy of the visualization of bone marrow edema by including patients who are scheduled for a ct scan to exclude or further characterize a fracture. after giving informed consent, the ct scan will be performed using a dose-neutral dual-energy-/multi-energy-/spectral-ct acquisition technique. if the patient undergoes mri of the same region within 7 days, this scan will be used as a gold-standard for bone marrow edema. this will allow the quantification of diagnostic accuracy.


Eligibility criteria:
inclusion criteria: * clinical suspicion for a fracture and * indication for ct confirmed by board-certified radiologist ('justified indication' according to german/european radiation protection law) and * patient (is able to give informed consent and) has given informed consent. exclusion criteria: * cardiorespiratory instability (as judged by the referring physician) * age \< 18 years * known or suspected pregnancy * known bone metastases of a malignant disease * known rheumatic disease * metal implants in the region to be scanned * surgical intervention over the last 12 months in the region to be scanned * contraindications for mri

Keywords: spectral ct multi-energy ct dual-energy ct bone marrow edema
county medical community-based, cardiovascular risk stratified integrated care model: a pragmatic cluster randomised control trial

Conditions: Hypertension; Diabetes Mellitus Type 2; Cardiovascular Diseases

Summary: the goal of this cluster randomized trial is to evaluate the effectiveness of the risima model based on an integrated county healthcare consortium implemented by multi-level family health teams (fhts)on patients with diabetes and/or hypertension, including cvd risk assessment, treatment, and management.


Eligibility criteria:
inclusion criteria: 1. aged between 40 and 70 years old; 2. patients with hypertension or diabetes; 3. permanent residents of the county where the research is conducted; 4. already signed up with the family doctor team in the township where the research is located. exclusion criteria: 1. unable to independently carry out the interventions required for the study; 2. residing far from the village or township health center where the research is located, making it difficult to cooperate with visits; 3. patients who refuse to participate; 4. patients with comorbidities such as cancer that may interfere with the study visits or intervention effects; 5. pregnant or lactating women
retrospective study of psychoattitudinal patterns in patients with fibromyalgia receiving antalgic therapy

Conditions: Analgesia; Fibromyalgia; Pain, Chronic; Pain Syndrome

Summary: fibromyalgia (fm) is a widespread and invalidating disease that requires a multidisciplinary approach. particularly, the psychiatric component seems to influence the algological management of these patients. since january 2018, the hads, sf-36, imsa, tci psycho-attitudinal questionnaires have been introduced in the pain therapy unit of policlinico sant'orsola-malpighi in an attempt to improve the care of patients diagnosed with fm. the aim of the study is to identify, through retrospective evaluation of tci tests and its subdomains, compiled by patients with fm diagnosis, pain avoidance and pain persistance personality patterns, indicated in the literature. anxiety and depression incidence is also observed through retrospective evaluation of hads tests. patients in the antalgic therapy outpatient clinic diagnosed with fm, aged ≥18 years, who have completed selfadministered psychoattitudinal tests from january 2018 to january 2019 were considered. the data were collected in aggregate and extrapolated anonymously.


Eligibility criteria:
inclusion criteria: * diagnosis of fibromyalgia * years ≥ 18 exclusion criteria: * not present

Keywords: fibromyalgia pain, chronic analgesia